Assertio Holdings, Inc. (NASDAQ:ASRT) Short Interest Down 11.5% in November

Assertio Holdings, Inc. (NASDAQ:ASRT - Get Free Report) was the target of a large decrease in short interest in November. As of November 30th, there was short interest totalling 5,540,000 shares, a decrease of 11.5% from the November 15th total of 6,260,000 shares. Based on an average trading volume of 683,000 shares, the short-interest ratio is currently 8.1 days.

Assertio Stock Down 3.3 %

Shares of ASRT stock traded down $0.03 on Friday, hitting $0.92. The stock had a trading volume of 1,109,591 shares, compared to its average volume of 929,948. Assertio has a 52-week low of $0.73 and a 52-week high of $1.80. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.57 and a current ratio of 2.01. The firm has a market capitalization of $87.84 million, a price-to-earnings ratio of -1.26 and a beta of 0.82. The stock's 50 day moving average is $1.01 and its 200-day moving average is $1.17.

Assertio (NASDAQ:ASRT - Get Free Report) last released its earnings results on Monday, November 11th. The company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.02. The firm had revenue of $29.20 million during the quarter, compared to the consensus estimate of $29.29 million. Assertio had a positive return on equity of 3.79% and a negative net margin of 54.46%. During the same period in the prior year, the firm posted ($0.01) earnings per share. As a group, research analysts expect that Assertio will post -0.15 earnings per share for the current year.

Insider Transactions at Assertio

In other news, Director Heather L. Mason acquired 75,000 shares of Assertio stock in a transaction that occurred on Monday, November 18th. The stock was purchased at an average price of $0.80 per share, for a total transaction of $60,000.00. Following the purchase, the director now directly owns 287,650 shares in the company, valued at $230,120. The trade was a 35.27 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 3.20% of the company's stock.

Hedge Funds Weigh In On Assertio

Several hedge funds have recently bought and sold shares of ASRT. Thurston Springer Miller Herd & Titak Inc. boosted its position in shares of Assertio by 304.0% during the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 50,500 shares of the company's stock valued at $60,000 after acquiring an additional 38,000 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Assertio during the 2nd quarter worth approximately $77,000. Vanguard Group Inc. lifted its stake in Assertio by 0.8% in the first quarter. Vanguard Group Inc. now owns 4,919,614 shares of the company's stock valued at $4,719,000 after acquiring an additional 41,071 shares during the last quarter. Point72 DIFC Ltd bought a new stake in Assertio in the second quarter valued at approximately $40,000. Finally, Renaissance Technologies LLC raised its position in shares of Assertio by 13.7% in the second quarter. Renaissance Technologies LLC now owns 2,377,614 shares of the company's stock valued at $2,948,000 after purchasing an additional 285,655 shares during the period. 48.96% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. HC Wainwright restated a "buy" rating and set a $4.00 target price on shares of Assertio in a research report on Monday, November 25th. StockNews.com upgraded Assertio from a "hold" rating to a "buy" rating in a research report on Wednesday, November 13th.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.